These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31354551)

  • 1. Early Substance Use Cessation Improves Cognition-10 Years Outcome in First-Episode Psychosis Patients.
    Weibell MA; Johannessen JO; Auestad B; Bramness J; Brønnick K; Haahr U; Joa I; Larsen TK; Melle I; Opjordsmoen S; Rund BR; Røssberg JI; Simonsen E; Vaglum P; Stain H; Friis S; Hegelstad WTV
    Front Psychiatry; 2019; 10():495. PubMed ID: 31354551
    [No Abstract]   [Full Text] [Related]  

  • 2. The Effect of Substance Use on 10-Year Outcome in First-Episode Psychosis.
    Weibell MA; Hegelstad WTV; Auestad B; Bramness J; Evensen J; Haahr U; Joa I; Johannessen JO; Larsen TK; Melle I; Opjordsmoen S; Rund BR; Simonsen E; Vaglum P; McGlashan T; McGorry P; Friis S
    Schizophr Bull; 2017 Jul; 43(4):843-851. PubMed ID: 28199703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ten year neurocognitive trajectories in first-episode psychosis.
    Barder HE; Sundet K; Rund BR; Evensen J; Haahr U; Ten Velden Hegelstad W; Joa I; Johannessen JO; Langeveld J; Larsen TK; Melle I; Opjordsmoen S; Røssberg JI; Simonsen E; Vaglum P; McGlashan T; Friis S
    Front Hum Neurosci; 2013; 7():643. PubMed ID: 24109449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neurocognition and Duration of Psychosis: A 10-year Follow-up of First-Episode Patients.
    Rund BR; Barder HE; Evensen J; Haahr U; ten Velden Hegelstad W; Joa I; Johannessen JO; Langeveld J; Larsen TK; Melle I; Opjordsmoen S; Røssberg JI; Simonsen E; Sundet K; Vaglum P; McGlashan T; Friis S
    Schizophr Bull; 2016 Jan; 42(1):87-95. PubMed ID: 26101305
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cognitive functioning in young people with first episode psychosis: relationship to diagnosis and clinical characteristics.
    Fitzgerald D; Lucas S; Redoblado MA; Winter V; Brennan J; Anderson J; Harris A
    Aust N Z J Psychiatry; 2004 Jul; 38(7):501-10. PubMed ID: 15255822
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neurocognitive development in first episode psychosis 5 years follow-up: associations between illness severity and cognitive course.
    Barder HE; Sundet K; Rund BR; Evensen J; Haahr U; Ten Velden Hegelstad W; Joa I; Johannessen JO; Langeveld H; Larsen TK; Melle I; Opjordsmoen S; Røssberg JI; Simonsen E; Vaglum P; McGlashan T; Friis S
    Schizophr Res; 2013 Sep; 149(1-3):63-9. PubMed ID: 23810121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neurocognitive dysfunction in first-episode psychosis: correlates with symptoms, premorbid adjustment, and duration of untreated psychosis.
    Rund BR; Melle I; Friis S; Larsen TK; Midbøe LJ; Opjordsmoen S; Simonsen E; Vaglum P; McGlashan T
    Am J Psychiatry; 2004 Mar; 161(3):466-72. PubMed ID: 14992972
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Persistence of psychotic symptoms as an indicator of cognitive impairment in methamphetamine users.
    Chen CK; Lin SK; Chen YC; Huang MC; Chen TT; Ree SC; Wang LJ
    Drug Alcohol Depend; 2015 Mar; 148():158-64. PubMed ID: 25601645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identifying neurocognitive markers for outcome prediction of global functioning in individuals with first-episode and ultra-high-risk for psychosis.
    Sawada K; Kanehara A; Sakakibara E; Eguchi S; Tada M; Satomura Y; Suga M; Koike S; Kasai K
    Psychiatry Clin Neurosci; 2017 May; 71(5):318-327. PubMed ID: 28294477
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychosocial functioning in first-episode psychosis and associations with neurocognition, social cognition, psychotic and affective symptoms.
    Stouten LH; Veling W; Laan W; van der Helm M; van der Gaag M
    Early Interv Psychiatry; 2017 Feb; 11(1):23-36. PubMed ID: 25585960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cognitive course in first-episode psychosis and clinical correlates: A 4 year longitudinal study using the MATRICS Consensus Cognitive Battery.
    Kenney J; Anderson-Schmidt H; Scanlon C; Arndt S; Scherz E; McInerney S; McFarland J; Byrne F; Ahmed M; Donohoe G; Hallahan B; McDonald C; Cannon DM
    Schizophr Res; 2015 Dec; 169(1-3):101-108. PubMed ID: 26416442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The course of neurocognitive functioning in first-episode psychosis and its relation to premorbid adjustment, duration of untreated psychosis, and relapse.
    Rund BR; Melle I; Friis S; Johannessen JO; Larsen TK; Midbøe LJ; Opjordsmoen S; Simonsen E; Vaglum P; McGlashan T
    Schizophr Res; 2007 Mar; 91(1-3):132-40. PubMed ID: 17258891
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Meta-analysis of neurocognition in young psychosis patients with current cannabis use.
    Bogaty SER; Lee RSC; Hickie IB; Hermens DF
    J Psychiatr Res; 2018 Apr; 99():22-32. PubMed ID: 29407284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretreatment predictors of cognitive deficits in early psychosis.
    González-Blanch C; Crespo-Facorro B; Alvarez-Jiménez M; Rodríguez-Sánchez JM; Pelayo-Terán JM; Pérez-Iglesias R; Vázquez-Barquero JL
    Psychol Med; 2008 May; 38(5):737-46. PubMed ID: 17922942
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurocognition as a predictor of transition to psychotic disorder and functional outcomes in ultra-high risk participants: Findings from the NEURAPRO randomized clinical trial.
    Bolt LK; Amminger GP; Farhall J; McGorry PD; Nelson B; Markulev C; Yuen HP; Schäfer MR; Mossaheb N; Schlögelhofer M; Smesny S; Hickie IB; Berger GE; Chen EYH; de Haan L; Nieman DH; Nordentoft M; Riecher-Rössler A; Verma S; Thompson A; Yung AR; Allott KA
    Schizophr Res; 2019 Apr; 206():67-74. PubMed ID: 30558978
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cognitive and Global Functioning in Patients With First-Episode Psychosis Stratified by Level of Negative Symptoms. A 10-Year Follow-Up Study.
    Engen MJ; Vaskinn A; Melle I; Færden A; Lyngstad SH; Flaaten CB; Widing LH; Wold KF; Åsbø G; Haatveit B; Simonsen C; Ueland T
    Front Psychiatry; 2022; 13():841057. PubMed ID: 35401286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reward Learning, Neurocognition, Social Cognition, and Symptomatology in Psychosis.
    Lewandowski KE; Whitton AE; Pizzagalli DA; Norris LA; Ongur D; Hall MH
    Front Psychiatry; 2016; 7():100. PubMed ID: 27378952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship of early premorbid adjustment with negative symptoms and cognitive functions in first-episode schizophrenia: a prospective three-year follow-up study.
    Chang WC; Tang JY; Hui CL; Wong GH; Chan SK; Lee EH; Chen EY
    Psychiatry Res; 2013 Oct; 209(3):353-60. PubMed ID: 23473654
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.